case_images: PMC10576154_01
case_images: Radiologic images, timeline and changes in the CEA level during the patient's clinical course.
case_images: LCTT-14-79-g0001.jpg
case_images: PMC10576154_01_LCTT-14-79-g0001.jpg
case_images: f0001
case_images: In June 2021, a 78-year-old male was admitted to our hospital because of sternal pain, chest computed tomography (CT) indicated a right upper lobe mass (27 x 18 mm) (Figure 1) and pathology showed moderately differentiated lung adenocarcinoma.
case_images: EGFR S645C and EGFR L858R detected in lung tissue (July 2021), plasma (January 2022) and pleural fluid (January 2022).
case_images: LCTT-14-79-g0002.jpg
case_images: PMC10576154_01_LCTT-14-79-g0002.jpg
case_images: f0002
case_images: Considering that EGFR p.L858R is a common therapeutic target for lung adenocarcinoma and that there are multiple approved drugs, the patient received osimertinib (80 mg once daily) as the first-line therapy in July 2021 (Figure 2). 